To learn more about Oncology-specific Investor events and information, visit the Takeda Oncology Investor Relations page
Takeda Oncology seeks partnerships for novel, innovative, first-in-class and/or best-in-class discovery and clinical stage oncology opportunities that target indications / settings of unmet medical need and complement Takeda’s research expertise and commercial footprint, in particular in hematological malignancies and lung cancer. Takeda Oncology is open to considering clinical stage opportunities in other solid tumors which have high unmet medical need.
Takeda’s discovery and early development efforts are focused on transformational approaches leveraging the innate immune system and Takeda continues to seek innovative technologies to augment these next generation platforms. Watch our Takeda Oncology Strategic Update from June 2021 and read about how we’re pursuing cancer breakthroughs with novel immune-oncology approached in this article.
Learn more about partnering with Takeda.